Hyperfine trading spiked on algorithms caching ‘AI,’ says B. Riley

B. Riley analyst Yuan Zhi reiterates a Buy rating on Hyperfine (HYPR) with a $1 price target after the company’s premium Swoop received FDA 510k approval weeks ahead of schedule. The new next-generation MRI system includes a new scanner and Optive artificial intelligence software, producing the highest level of image quality and uniformity, the analyst tells investors in a research note. The firm says Hyperfine kept the hardware development confidential up until yesterday, so it is likely not on many investor radars. Riley points out the trading volume of Hyperfine on Monday was greater than 100M shares, more than the entire float. This trading abnormality could be related to trading algorithms catching the keyword “AI,” the firm contends.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on HYPR:

Disclaimer & DisclosureReport an Issue

• Hyperfine announces FDA clearance of Swoop system

• Hyperfine announces FDA clearance of next-generation software

• Hyperfine Chairperson R. Scott Huennekens Resigns

• Hyperfine Holds Annual Stockholders Meeting

• Hyperfine Inc. Earnings Call: Transition and Growth